other material
confidence high
sentiment positive
materiality 0.50
BioAge Labs doses first patient in Phase 2 QUELL-DME trial of oral BGE-102 for DME
BioAge Labs, Inc.
- First participant dosed in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema.
- Approximately 180 participants randomized 1:1:1: anti-VEGF plus oral placebo; anti-VEGF plus BGE-102 90 mg daily; sham intravitreal injection plus BGE-102 90 mg daily.
- 12 weeks of once-daily dosing with a four-week follow-up; primary endpoint is change in best-corrected visual acuity at week 12, with retinal and biomarker exploratory endpoints.
- Topline results expected in the second half of 2027, and are expected to inform development strategy in other NLRP3-driven retinal diseases including geographic atrophy.